Increasing burden of liver disease in patients with HIV infection (Q37860640)

24 August 2017

1 reference

title

Increasing burden of liver disease in patients with HIV infection (English)

1 reference

24 August 2017

0 references

0 references

1 reference

Deepak Joshi

1

1 reference

24 August 2017

John O'Grady

2

1 reference

24 August 2017

Doug Dieterich

3

1 reference

24 August 2017

Brian Gazzard

4

1 reference

24 August 2017

Kosh Agarwal

5

1 reference

24 August 2017

language of work or name

English

0 references

publication date

1 April 2011

1 reference

24 August 2017

1 reference

24 August 2017

377

1 reference

24 August 2017

9772

1 reference

24 August 2017

1198-1209

1 reference

Changes in the cause of death among HIV positive subjects across Europe: results from the EuroSIDA study

24 August 2017

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2810%2962001-6

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2810%2962001-6

7 January 2021

Liver disease as a major cause of death among HIV infected patients: role of hepatitis C and B viruses and alcohol

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2810%2962001-6

7 January 2021

Viral hepatitis in HIV infection

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2810%2962001-6

7 January 2021

Liver fibrosis progression in human immunodeficiency virus and hepatitis C virus coinfected patients. The Multivirc Group

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2810%2962001-6

7 January 2021

HIV coinfection shortens the survival of patients with hepatitis C virus-related decompensated cirrhosis.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2810%2962001-6

7 January 2021

Clinical progression of hepatitis C virus-related chronic liver disease in human immunodeficiency virus-infected patients undergoing highly active antiretroviral therapy.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2810%2962001-6

7 January 2021

The model for end-stage liver disease (MELD)

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2810%2962001-6

7 January 2021

MELD score is an important predictor of pretransplantation mortality in HIV-infected liver transplant candidates

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2810%2962001-6

7 January 2021

The model for end-stage liver disease score is the best prognostic factor in human immunodeficiency virus 1-infected patients with end-stage liver disease: a prospective cohort study

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2810%2962001-6

7 January 2021

Survival of HIV-infected patients with compensated liver cirrhosis

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2810%2962001-6

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2810%2962001-6

7 January 2021

Prevalence of risk factors for hepatitis C virus in HIV-infected and HIV/hepatitis C virus-coinfected patients

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2810%2962001-6

7 January 2021

Increasing incidence of acute hepatitis C in individuals diagnosed with primary HIV in the United Kingdom

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2810%2962001-6

7 January 2021

Acute hepatitis C in a contemporary US cohort: modes of acquisition and factors influencing viral clearance

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2810%2962001-6

7 January 2021

Intermittent detection of hepatitis C virus (HCV) in semen from men with human immunodeficiency virus type 1 (HIV-1) and HCV.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2810%2962001-6

7 January 2021

Recent epidemic of acute hepatitis C virus in HIV-positive men who have sex with men linked to high-risk sexual behaviours

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2810%2962001-6

7 January 2021

A cluster of acute hepatitis C virus infection among men who have sex with men--results from contact tracing and public health implications

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2810%2962001-6

7 January 2021

Coinfection of hepatitis C virus with human immunodeficiency virus and progression to AIDS. Italian Seroconversion Study.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2810%2962001-6

7 January 2021

Clinical progression, survival, and immune recovery during antiretroviral therapy in patients with HIV-1 and hepatitis C virus coinfection: the Swiss HIV Cohort Study

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2810%2962001-6

7 January 2021

Impact of hepatitis C virus on immune restoration in HIV-infected patients who start highly active antiretroviral therapy: a meta-analysis

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2810%2962001-6

7 January 2021

Influence of human immunodeficiency virus infection on the course of hepatitis C virus infection: a meta-analysis

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2810%2962001-6

7 January 2021

Documented rapid course of hepatic fibrosis between two biopsies in patients coinfected by HIV and HCV despite high CD4 cell count

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2810%2962001-6

7 January 2021

Human immunodeficiency virus infection modifies the natural history of chronic parenterally-acquired hepatitis C with an unusually rapid progression to cirrhosis

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2810%2962001-6

7 January 2021

HIV antigens can induce TGF-beta(1)-producing immunoregulatory CD8+ T cells

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2810%2962001-6

7 January 2021

Immune stimulation of hepatic fibrogenesis by CD8 cells and attenuation by transgenic interleukin-10 from hepatocytes

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2810%2962001-6

7 January 2021

Comparison of HCV-specific intrahepatic CD4+ T cells in HIV/HCV versus HCV.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2810%2962001-6

7 January 2021

Intrahepatic cytokine expression is downregulated during HCV/HIV co-infection

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2810%2962001-6

7 January 2021

Hepatitis C virus infection and diabetes: direct involvement of the virus in the development of insulin resistance

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2810%2962001-6

7 January 2021

HIV-1 Entry Cofactor: Functional cDNA Cloning of a Seven-Transmembrane, G Protein-Coupled Receptor

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2810%2962001-6

7 January 2021

HIV increases HCV replication in a TGF-beta1-dependent manner.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2810%2962001-6

7 January 2021

gp120 modulates the biology of human hepatic stellate cells: a link between HIV infection and liver fibrogenesis

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2810%2962001-6

7 January 2021

Human immunodeficiency virus-related microbial translocation and progression of hepatitis C.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2810%2962001-6

7 January 2021

Genetic variation in IL28B predicts hepatitis C treatment-induced viral clearance

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2810%2962001-6

7 January 2021

Genome-wide association of IL28B with response to pegylated interferon-alpha and ribavirin therapy for chronic hepatitis C

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2810%2962001-6

7 January 2021

Genetic variation in IL28B is associated with chronic hepatitis C and treatment failure: a genome-wide association study

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2810%2962001-6

7 January 2021

Association of a single nucleotide polymorphism near the interleukin-28B gene with response to hepatitis C therapy in HIV/hepatitis C virus-coinfected patients.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2810%2962001-6

7 January 2021

Liver fibrosis in patients with chronic hepatitis C and persistently normal liver enzymes: influence of HIV infection

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2810%2962001-6

7 January 2021

The use of transient elastometry for assessing liver fibrosis in patients with HIV and hepatitis C virus coinfection.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2810%2962001-6

7 January 2021

Role of weight-based ribavirin dosing and extended duration of therapy in chronic hepatitis C in HIV-infected patients: the PRESCO trial

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2810%2962001-6

7 January 2021

Peginterferon Alfa-2a plus ribavirin for chronic hepatitis C virus infection in HIV-infected patients

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2810%2962001-6

7 January 2021

Randomized trial comparing pegylated interferon alpha-2b versus pegylated interferon alpha-2a, both plus ribavirin, to treat chronic hepatitis C in human immunodeficiency virus patients

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2810%2962001-6

7 January 2021

Peginterferon Alfa-2a plus ribavirin versus interferon alfa-2a plus ribavirin for chronic hepatitis C in HIV-coinfected persons

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2810%2962001-6

7 January 2021

Pegylated interferon alfa-2b vs standard interferon alfa-2b, plus ribavirin, for chronic hepatitis C in HIV-infected patients: a randomized controlled trial

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2810%2962001-6

7 January 2021

Viral kinetics and early prediction of nonresponse to peg-IFN-alpha-2b plus ribavirin in HCV genotypes 1/4 according to HIV serostatus

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2810%2962001-6

7 January 2021

British HIV Association guidelines for the management of coinfection with HIV-1 and hepatitis B or C virus 2010

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2810%2962001-6

7 January 2021

Peginterferon alfa-2b or alfa-2a with ribavirin for treatment of hepatitis C infection

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2810%2962001-6

7 January 2021

Sustained virological response to interferon plus ribavirin reduces liver-related complications and mortality in patients coinfected with human immunodeficiency virus and hepatitis C virus

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2810%2962001-6

7 January 2021

Efficacy of early treatment of acute hepatitis C infection with pegylated interferon and ribavirin in HIV-infected patients

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2810%2962001-6

7 January 2021

Increased mitochondrial toxicity with ribavirin in HIV/HCV coinfection

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2810%2962001-6

7 January 2021

Risk factors for hepatic decompensation in patients with HIV/HCV coinfection and liver cirrhosis during interferon-based therapy

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2810%2962001-6

7 January 2021

Spontaneous hepatic decompensation in patients coinfected with HIV and hepatitis C virus during interferon-ribavirin combination treatment

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2810%2962001-6

7 January 2021

Prevalence of chronic hepatitis B and incidence of acute hepatitis B infection in human immunodeficiency virus-infected subjects

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2810%2962001-6

7 January 2021

Interactions between HIV and hepatitis B virus in homosexual men: effects on the natural history of infection

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2810%2962001-6

7 January 2021

Influence of human immunodeficiency virus infection on chronic hepatitis B in homosexual men.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2810%2962001-6

7 January 2021

HIV-1, hepatitis B virus, and risk of liver-related mortality in the Multicenter Cohort Study (MACS).

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2810%2962001-6

7 January 2021

Presentation and outcome of hepatocellular carcinoma in HIV-infected patients: A U.S.–Canadian multicenter study

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2810%2962001-6

7 January 2021

Hepatitis B and long-term HIV outcomes in coinfected HAART recipients

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2810%2962001-6

7 January 2021

Frequent hepatitis B virus rebound among HIV-hepatitis B virus-coinfected patients following antiretroviral therapy interruption

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2810%2962001-6

7 January 2021

Predicting cirrhosis risk based on the level of circulating hepatitis B viral load

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2810%2962001-6

7 January 2021

Care of HIV patients with chronic hepatitis B: updated recommendations from the HIV-Hepatitis B Virus International Panel.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2810%2962001-6

7 January 2021

EASL Clinical Practice Guidelines: management of chronic hepatitis B.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2810%2962001-6

7 January 2021

Dual efficacy of lamivudine treatment in human immunodeficiency virus/hepatitis B virus-coinfected persons in a randomized, controlled study (CAESAR). The CAESAR Coordinating Committee

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2810%2962001-6

7 January 2021

Development of hepatitis B virus resistance for lamivudine in chronic hepatitis B patients co-infected with the human immunodeficiency virus in a Dutch cohort

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2810%2962001-6

7 January 2021

Long-term therapy with adefovir dipivoxil for HBeAg-negative chronic hepatitis B.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2810%2962001-6

7 January 2021

Randomized controlled study of tenofovir and adefovir in chronic hepatitis B virus and HIV infection: ACTG A5127.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2810%2962001-6

7 January 2021

Hazardous alcohol use: a risk factor for non-adherence and lack of suppression in HIV infection

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2810%2962001-6

7 January 2021

Hazardous drinking is associated with an elevated aspartate aminotransferase to platelet ratio index in an urban HIV-infected clinical cohort

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2810%2962001-6

7 January 2021

Influence of liver fibrosis on highly active antiretroviral therapy-associated hepatotoxicity in patients with HIV and hepatitis C virus coinfection

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2810%2962001-6

7 January 2021

Predictors of antiretroviral-related hepatotoxicity in the adult AIDS Clinical Trial Group (1989-1999).

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2810%2962001-6

7 January 2021

Elevated liver enzymes following initiation of antiretroviral therapy

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2810%2962001-6

7 January 2021

Severe hepatotoxicity associated with nevirapine use in HIV-infected subjects

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2810%2962001-6

7 January 2021

Hypersensitivity syndrome associated with efavirenz therapy

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2810%2962001-6

7 January 2021

Long-term body composition and metabolic changes in antiretroviral naive persons randomized to protease inhibitor-, nonnucleoside reverse transcriptase inhibitor-, or protease inhibitor plus nonnucleoside reverse transcriptase inhibitor-based strate

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2810%2962001-6

7 January 2021

Hepatic steatosis and antiretroviral drug use among adults coinfected with HIV and hepatitis C virus

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2810%2962001-6

7 January 2021

Hepatotoxicity of antiretrovirals: incidence, mechanisms and management

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2810%2962001-6

7 January 2021

Incidence and risk factors for chronic elevation of alanine aminotransferase levels in HIV-infected persons without hepatitis b or c virus co-infection

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2810%2962001-6

7 January 2021

Hepatotoxicity of antiretroviral drugs in HIV HCV patients with congenital coagulopathies followed at an Haemophilia Unit during a decade

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2810%2962001-6

7 January 2021

Hepatitis B and C virus co-infection and the risk for hepatotoxicity of highly active antiretroviral therapy in HIV-1 infection

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2810%2962001-6

7 January 2021

Hepatotoxicity associated with nevirapine or efavirenz-containing antiretroviral therapy: role of hepatitis C and B infections

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2810%2962001-6

7 January 2021

Liver toxicity induced by non-nucleoside reverse transcriptase inhibitors.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2810%2962001-6

7 January 2021

Risk and determinants of developing severe liver toxicity during therapy with nevirapine-and efavirenz-containing regimens in HIV-infected patients

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2810%2962001-6

7 January 2021

Drug-induced liver injury associated with antiretroviral therapy that includes HIV-1 protease inhibitors

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2810%2962001-6

7 January 2021

Hepatotoxicity associated with antiretroviral therapy containing dual versus single protease inhibitors in individuals coinfected with hepatitis C virus and human immunodeficiency virus

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2810%2962001-6

7 January 2021

Severe Liver Disease Associated With Prolonged Exposure to Antiretroviral Drugs

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2810%2962001-6

7 January 2021

Association of noncirrhotic portal hypertension in HIV-infected persons and antiretroviral therapy with didanosine: a nested case-control study.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2810%2962001-6

7 January 2021

Noncirrhotic portal hypertension in patients with human immunodeficiency virus-1 infection

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2810%2962001-6

7 January 2021

Noncirrhotic portal hypertension in HIV-infected patients: unique clinical and pathological findings.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2810%2962001-6

7 January 2021

Nodular regenerative hyperplasia: a new serious antiretroviral drugs side effect?

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2810%2962001-6

7 January 2021

Hepatoportal sclerosis as a cause of noncirrhotic portal hypertension in patients with HIV.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2810%2962001-6

7 January 2021

Nodular regenerative hyperplasia is a new cause of chronic liver disease in HIV-infected patients

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2810%2962001-6

7 January 2021

Nonalcoholic fatty liver disease among HIV-infected persons

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2810%2962001-6

7 January 2021

Nonalcoholic fatty liver disease: a spectrum of clinical and pathological severity

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2810%2962001-6

7 January 2021

GI epidemiology: nonalcoholic fatty liver disease

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2810%2962001-6

7 January 2021

High prevalence of the metabolic syndrome in HIV-infected patients: impact of different definitions of the metabolic syndrome

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2810%2962001-6

7 January 2021

Nonalcoholic fatty liver disease in HIV-infected patients referred to a metabolic clinic: prevalence, characteristics, and predictors

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2810%2962001-6

7 January 2021

HIV-positive patients with nonalcoholic fatty liver disease have a lower body mass index and are more physically active than HIV-negative patients

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2810%2962001-6

7 January 2021

Liver damage underlying unexplained transaminase elevation in human immunodeficiency virus-1 mono-infected patients on antiretroviral therapy

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2810%2962001-6

7 January 2021

Enhancement of chemical hepatocarcinogenesis by the HIV-1 tat gene

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2810%2962001-6

7 January 2021

Emerging role of hepatocellular carcinoma among liver-related causes of deaths in HIV-infected patients: The French national Mortalité 2005 study

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2810%2962001-6

7 January 2021

Hepatocellular carcinoma in HIV-infected patients: epidemiological features, clinical presentation and outcome

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2810%2962001-6

7 January 2021

Survival of Human Immunodeficiency Virus–Infected Liver Transplant Recipients

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2810%2962001-6

7 January 2021

Survival and recurrence of hepatitis C after liver transplantation in patients coinfected with human immunodeficiency virus and hepatitis C virus

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2810%2962001-6

7 January 2021

Survival of liver transplant patients coinfected with HIV and HCV is adversely impacted by recurrent hepatitis C.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2810%2962001-6

7 January 2021

Guidelines for liver transplantation in patients with HIV infection (2005)

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2810%2962001-6

7 January 2021

Impact of human immunodeficiency virus on survival after liver transplantation: analysis of United Network for Organ Sharing database

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2810%2962001-6

7 January 2021

Outcome of patients with hepatitis B virus and human immunodeficiency virus infections referred for liver transplantation

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2810%2962001-6

7 January 2021

Safety and efficacy of raltegravir in HIV-infected transplant patients cotreated with immunosuppressive drugs.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2810%2962001-6

7 January 2021

10.1016/S0140-6736(10)62001-6

Identifiers

DOI

1 reference

24 August 2017

1 reference